Outpatient Anticoagulation Management by du Breuil, MD, Anne
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Family & Community Medicine 
Presentations and Grand Rounds Department of Family & Community Medicine 
6-16-2021 
Outpatient Anticoagulation Management 
Anne du Breuil, MD 
Follow this and additional works at: https://jdc.jefferson.edu/fmlectures 
 Part of the Family Medicine Commons, and the Primary Care Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Family & Community Medicine Presentations and Grand Rounds by an 






Anne du Breuil MD
Assistant Professor
Department of Family and
Community Medicine
Sidney Kimmel Medical College
at Thomas Jefferson University
Disclosure
• I have no actual or potential conflict of interest in 






• More team based anticoagulation management
• Nurse coordinator for anticoagulation at JFMA will be Catherine Disandro (Katie) 
• Anticoagulation patients will be managed by a combination of the PCP and the 
nurse coordinator so each PCP will be receiving a list of their patients on warfarin 
soon and eventually those patients on DOACs
• The majority of the time the patients will see their PCP for anticoagulation 
management
• There will also be a nurse run with resident and pharmacy resident support 
anticoagulation clinic on Thursday afternoons for patients who need more 
supervision or when the PCP is unavailable.
• The anticoagulation nurse and medical assistant (Shakia Miller) will review home 
draw and home INR machine results and will contact the patients. 
• Warfarin doses will be adjusted by the nurse per protocol. The PCP will be 
contacted as needed. 
• The anticoagulation nurse and medical assistant will also keep track of 




•Anticoagulation Module in Epic
•Brief summary of Direct Oral Anticoagulants 
(DOACs)
•Brief Perioperative Anticoagulation Tips
US emergency department visits for oral anticoagulant related bleeding, by year, 2011–2017. 
Estimates from the National Electronic Injury Surveillance System–Cooperative Adverse Drug
Event Surveillance project, CDC. Excludes n = 40 cases implicating both warfarin and a DOAC 
(2011, n = 2 cases; 2013, n = 3 cases; 2014, n = 7 cases; 2015, n = 8 cases; 2016, n = 9 cases; 
2017, n = 11 cases). DOAC, direct-acting oral anticoagulant.
Geller et al
Indications for Oral Anticoagulation
• Treatment of existing thrombosis
Acute venous thromboembolism (VTE)
• Primary prevention of thrombosis
Patients with atrial fibrillation (AFib) with an increased risk of stroke
Patients with mechanical heart valves
Extended VTE prophylaxis following major orthopedic surgeries
• Secondary prevention of thrombosis
Patients with a history of VTE for which benefits of treatment outweigh risks
Patients with Afib and a history of cardioembolic stroke
• Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic 
events such as stroke or systemic embolization after myocardial infarction
• Reduction in risk of major cardiovascular events in patients with coronary artery 
disease (CAD) or peripheral artery disease (PAD)
2020 U.S. Food & Drug Administration
Direct Acting Oral 
Anticoagulants 
(DOACs) and Vitamin K 
Antagonists
• Direct Thrombin Inhibitor
• Dabigatran




• Factors II, VII, IX, and X 
Inhibitors
• Vitamin K antagonists 
–Warfarin
• John N. Makaryus,Jonathan L. Halperin&Joe F. Lau, Oral 
anticoagulants in the management of venous 
thromboembolism, Nature Reviews CardiologyVolume 10
2020 U.S. Food & Drug Administration
Warfarin
ØInterferes with Vitamin K dependent clotting 
factors (II, VII, IX, X)
ØAntithrombotic effect measured by PT
ØInterlab variability in thromboplastins – INR
ØEarliest INR changes 24-36 hours after dose
ØAntithrombotic effect is not present until ~ 
day 5
Genetic Testing for
Warfarin Dosing (Not recommended)
Ø 2 Tests available
1. Sensitivity to warfarin - VKORC1 
(vitamin K epoxide reductase) test. 
VKORC1 is the gene that codes for 
enzyme at site where warfarin exerts 
effect
2. Rate of metabolizing warfarin –
CYP2C9 test. CYP2C9 is the liver 
enzyme which breaks down S-warfarin 
(more active half of warfarin).
Bussey HI et al. www.clotcare.com/clotcare/warfaringentictesting.aspx, July 2007
Vitamin K Epoxide Reductase VKORC1
Ø Sensitive (AA genotype) less warfarin
more common in Asians
Ø Resistant (GG genotype) more warfarin
more common in blacks
Ø In between (AG genotype) average 
warfarin
Bussey HI et al. www.clotcare.com/clotcare/warfaringentictesting.aspx, July 2007
CYP2C9 Variant
Ø Metabolize warfarin more slowly
Ø Accumulate warfarin in blood over a longer period of time
Ø Take longer to reach a stable INR – need more warfarin 
initially then may need to cut back on dose
Ø Slow metabolizers – lower dose warfarin maintenance
Bussey HI et al. www.clotcare.com/clotcare/warfaringentictesting.aspx, July 2007
Warfarin Dosing Regimen
Ø Highest in CYP2C9 homozygous for wild type compare to 
variants
Ø GG genotype>AG genotype>AA genotype
Ø Mean daily dose warfarin dose fell 0.5-0.7mg/decade 
between 20-90 years old
Ø Age, height, and CYP2C9 significantly contributed to S-
warfarin and total warfarin clearance
Ø Age and body size to R-warfarin clearance
Sconce EA et al. Blood 2005;106:2329-2333
Warfarin Medication Interactions
Ø Inhibition of Metabolism:
Metronidazole, trimethoprim/sulfa
Ø Potentiation:
Amiodarone long half-life 60 days
Ø Hepatic metabolism induced:
Barbiturates, carbamazepine, rifampin
Ø Increase metabolism of coagulation factors:
thyroxine
Ø Inhibition of platelet activity:
NSAIDS
Disease State Interactions
ØHepatic congestion (CHF, liver disease, 
cancer) – reduce warfarin metabolism
ØHyperthyroidism – Increase metabolism of 
coagulation facts
ØDiarrhea – loss of vitamin K foods
ØAnorexia – decreased intake vitamin K foods
Food Interactions
Ø Foods with high vitamin K content –
Ø Consistent amounts rather than avoiding completely
Enteral feeds with high vitamin K content
Avocados (large amounts), broccoli, brussel sprouts, cabbage, 
collard greens, raw endive, kale, bib leaf and red leaf lettuce, 




Drugs That Increase the Potency of Warfarin
Acetaminophen








































Drugs and Herbal Products That Decrease the 
Potency of Warfarin
Drugs Herbal products
Azathioprine (Imuran) Coenzyme Q10
Carbamazepine (Tegretol) Ginseng















Hip fracture surgery 2-3
Ø VTE and PE
DVT or PE 2-3
DURATION
25-35 days
At least 10 days
28-35 days
1st episode reversible factors: 3 
mos.
1st episode idiopathic: 6-12 mos.
Cancer pts: LMWH for 3-6 mos.
then warfarin indefinitely





High risk of stroke 2-3












Ø Valvular Heart Disease
Rheumatic mitral valve 2-3






St. Jude bileaflet 2-3
Carbomedics bileaflet 2-3




















































Ebell MH. Am Fam Physician 2005;71:1979-82
Initiating Warfarin
Therapy
Treatment of DVT and PE
Ø Initiate warfarin and LMWH (or UFH) on day 1
Ø Use 5 mg nomogram to initiate warfarin therapy 
and monitor INR per nomogram protocol to 
target of 2 – 3
Ø Stop LMWH or UFH after no less than 5 days 
and when INR stable at ≥ 2 or more for 2 
days
Ø Use elastic compression stockings 30-40mm at 
ankle to prevent post thrombotic syndrome
Ø Ambulate as tolerated
Warfarin Maintenance
ØMonitor initially twice weekly or more, weekly, 
every 2 weeks, every 3 weeks, but usually at least 
every 4 weeks
ØIncrease spacing depending on how many weeks 
the INR has been stable
ØCHEST Guidelines suggest longer intervals of up 
to 12 weeks may be considered in patients with 
consistently stable INRs
Adjusting Warfarin Dosing
ØOut of range INR’s – attempt to find 
cause
ØAdjust dose 5 to 20% of total weekly dose 
up or down
ØDo your dose adjustments if possible 
using the size warfarin pill the patient has
Questions to ask at each visit and to 
determine reason for abnormal INR
Ø 1) Any excessive bleeding or bruising?
Ø 2) Any missed or extra warfarin doses?
Ø 3) Any changes in medications?
Ø 4) Any changes in over the counter medications?
Ø 5) Any changes in diet?
Ø 6) Any illnesses?
Ø 7) Any upcoming dental or surgical procedures?
Ø 8) Any emergency room visits or hospitalizations?
Dosage Adjustment Algorithms
For target INR of 2.0 to 3.0, no bleeding
Ø INR< 1.5
Increase weekly total dose 10 to 20%; consider extra dose
Next INR 4 to 8 days
Ø INR 1.5 to 1.9
Increase weekly total dose 5 to 10%
Next INR 7 to 14 days
Ø INR 2.0 to 3.0 (or 1.8-1.9; 3.1-3.2)
No change
No. of consecutive in-range INRs x 1 wk (max: 4 wks)
Ø INR 3.1 to 3.9
Decrease weekly total dose 5 to 10%
Next INR 7 to 14 days
Ø 4.0 to 4.9
Hold for 0 to 1 day then decrease weekly total dose 10%
Next INR 4 to 8 days
Ebell MH. Am Fam Physician 2005;71:1979-82
Significantly Elevated INRs
Ø INR 5-8.9 (measurable) and no significant bleeding:
Omit 1 to 2 doses
Reduce total dose 10 to 20 percent
Monitor frequently
INR= 8.0 on Coaguchek monitor in office
MEANS IS 8 OR ABOVE NOT JUST 8.
Draw Stat PT/INR and send to Jefferson Lab
Keep patient in office
Ø INR ≥ 9 (or ≥ the highest # measured at lab)
Send to ER as INR could be as high as 20 and 
needs reversal
LOOK CAREFULLY AT THE INR RESULT: IF THERE IS A 
GREATER THAN (>) SIGN IN FRONT OF IT, THAT 
MEANS IT COULD BE UP TO AN INR OF 20.
Ebell MH. Am Fam Physician 2005;71:1979-82
Warfarin Reversal Agent
Ø Vitamin K
Indicated in patients treated with warfarin when reversal 
of the anticoagulant effects is needed (e.g., due to life-
threatening or uncontrolled bleeding). 
Ø Intracerebral hemorrhage: 
Replace clotting factors within 90 minutes of emergency 
department arrival.
PCC (Prothrombin complex concentrate) generally preferred 
to fresh frozen plasma to restore clotting factors in patients 
requiring urgent warfarin reversal.
Anticoagulation Module in EPIC
•Keeps track of all anticoagulation patients
•Shows patient’s warfarin regimen
•Sends a message to the INR reminder list in EPIC 
so patients who fail to check their INR are 
contacted.
•Prints out a warfarin calendar with the patient’s 
dosing regimen and their date of their next INR.
New Anticoagulation Patient
• Under Referrals you can chose to make an Anticoagulation 
Referral.
• Make sure and choose FAM 33 S 9th ST Anticoagulation
• You should also task Katie (Catherine DiSandro) 
• Please let Katie know about any new patient started on 
warfarin
• Include the duration of therapy if known and indication for 
therapy
• The patient will need an appointment soon and Katie or 
Shakia can help set this up.
Creating an Anticoagulation Episode
•Once the Anticoagulation Nurse receives an 
anticoagulation referral, an Anticoagulation Episode 
will be made. This Episode will continue as long as the 
patient remains on anticoagulation
• Though the module was designed for warfarin it can 
be used with minor modifications to remind us when 
our DOAC patients need to show up – either for lab 




“Rarely used” then 
“Quick Navigators” 
and open it and star it 
so it is easier to FIND.
Anticoagulation Module
Anticoag
In the module are 
various headings
Click on these headings 
to enter data:
1) Patient Findings













In order to keep track 
of patients and to give 
them home warfarin 
instructions, the 
tracking part of the 
module needs to be 
filled out at every visit.
The MA needs to 
enter the POC INR 
where it says POCT
This will both drop an 
order and enter the 
result.
If the INR is done 
at the same visit, it 
will automatically 
go to select an INR 
for dosing. 
Otherwise just 
click on the INR 
you will use.
If you are using the module 
for a patient who is on a 
DOAC select the No INR box.
Current 
Maintenance Plan
If you need to adjust 
the patient’s warfarin 
regimen, click on the 
current maintenance 
plan which on this 
one is 10 mg every 
Monday and Friday 
and 5 mg all the 
other days.
“Edit maintenance 
Plan” will pop up
1. Enter tablets patient has 
on hand
2. Choose every day or 
weekly
3. Enter number of each 
size tablet
4. Use “Do not use 
maintenance plan” for 
DOACs
5. Click on today and chart 
will autofill
Next pick the date for 
the next INR
“Critical” will pick a couple 
of days
“Fluctuating” will pick one 
week
“Stable” will pick 4 weeks
Then either click on the 
suggested INR date or 




1) Once the INR is overdue a 
message is sent to the INR 
Reminder Pool inbasket in 
EPIC.
2) If you do not put in the 
return date for the INR, it will 
go to the pool. 
3) To avoid extra work for 
staff and also remind patient 
when their INR is due please 
fill out the date of next INR.
After Visit Summary
The AVS will show:
1) Warfarin dosing including pill 
size and number
2) Date for return for the next 
INR.
3) This summary also 
demonstrates that a boost 
dose was given. You enter this 
by clicking on the box on the 
date in the tracer and a pop 
up will appear that you can 
then fill in the one day change 
in dose.
If you want this information 
to appear in your note chose 
the 
Amb J AC Physician Visit Note
If you chose this note you can still 
do everything you normally do 
during a regular visit. It does not 
limit you or make anticoagulation 
your primary problem.
The only difference is that it 
brings your anticoag
documentation into your office 
visit note.
Clinical Lab Recommendations Prior to and 
During Oral Anticoagulant Therapy
Warfarin
•CBC (complete blood 
count) annually
•PT (prothrombin time) 
see above





• Serum creatinine 
annually unless have CKD 
then more frequently 
depending on the level of 
CKD
• Liver function tests at 
least annually
2020 U. S. Food & Drug administration
Warfarin: Advantages and Disadvantages
Advantages
• Long track record with 
predictable benefits and 
results.
•Once daily dosing.
•Ability to readily measure 
anticoagulant effect with 
INR test.
Disadvantages
• Narrow therapeutic window.
• Diet, disease states, and drugs may 
significantly alter INR.
• INR must be monitored regularly.
• Maintaining INRs within the target 
range optimizes the balance of 
efficacy and safety. 
• Dosing schedule can be 
complicated.
• Contraindicated in pregnant 
women.
2020 U.S. Food & Drug Administration
DOACS: Advantages and Disadvantages
Advantages
• No regular laboratory monitoring for 
anticoagulant effect.
• Rapid onset/offset of action.
• Fewer drug interactions.
• Predictable pharmacokinetics.
• Efficacy and safety are at least as 
good as warfarin (for stroke 
prevention in atrial fibrillation, and 
treatment and secondary prevention 
of venous thromboembolism).
• Lower rates of stroke caused by 
bleeding in the brain.
Disadvantages
• No widely agreed on laboratory 
test to monitor anticoagulant 
effect.
• Some DOACS may cause upset 
stomach. 
• DOACs in general have a shorter 
half-life than warfarin, making 
missed doses more 
consequential.
• No adequate and well-controlled 
studies in pregnant women. 
Should only be used during 
pregnancy if the potential 
benefit outweighs the potential 
risk to the mother and fetus.
2020 U.S. Food & Drug Administration
DOACs and Approved Indications






















Reduce Risk of Major 
Cardiovascular 
Events in CAD and 
PAD patients (in 
combination with 
aspirin use)
Apixaban X X X X
Dabigatran X (hip) X X X
Edoxaban X X
Rivaroxaban X X X X X X
2020 U.S. Food & Drug Administration
Contraindications and Relative 
Contraindications to DOACs
• 1) Mechanical heart valves
• 2) Antiphospholipid syndrome
• 3) Obesity/cachexia
• 4) Gastric bypass
• 5) Cost
• 6) Drug interactions
• 7) Failure of DOACs
• 8) Patient preference
DOAC Monitoring
• In addition to laboratory monitoring parameters, a comprehensive 
DOAC monitoring approach should include the following items 
assessed at each follow-up:
• 1. Current health status.
• 2. Adherence and cost.
• 3. Bleeding/thromboembolic events.
• 4. Adverse effects.
• 5. Complete medication review for drug interactions.
• 6. Reassessment of appropriateness of therapy.
• 7. Repeat warranted laboratory parameters.
• 8. Continuing follow-up appointments for patients.
DOAC Safety Considerations and Interaction
• Improper Use of DOACS:
Only 70% of DOAC prescriptions were appropriate.
24% of patients received an inappropriate dose. Of this 24%: 
57% received a reduced dose with no clear indication.
43% received a dose that was not reduced while indicated. (Lavoie 2016)
• Dietary interactions to consider:
Dabigatran capsules must be swallowed whole and not opened due to the risk of 
increased absorption.
Rivaroxaban (15 and 20 mg) should be taken with food for adequate absorption.
• Disease state interactions include:
Renal function
Renal elimination differs among DOACs
From more to less renal elimination: dabigatran > edoxaban> rivaroxaban > apixaban
2020 U.S. Food & Drug Administration
Drug Interactions Effect of DOAC Recommendations
Dabigatran P-gp inhibitors Increase in concentration Reduce dose or avoid depending on renal function
P-gp inducers Significant reduction in 
concentration
Avoid use
Antacids Moderate reduction in 
concentration
No dosing adjustments required; consider spacing 
regiments by 2 hours
Apixaban Strong CYP3A4 inhibitor + 
P-gp inhibitor
Significant increase in 
concentration
Reduce dose or avoid use
Moderate CYP3A4 inhibitor + P-gp
inhibitor
Moderate increase in 
concentration
No precaution necessary
Avoid use in patient with severe renal insufficiency
Strong CYP3A4 inducer or 
P-gp inducer
Significant reduction in 
concentration
Avoid use
Rivaroxaban Strong CYP3A4 inhibitor + 
P-gp inhibitor
Significant increase in 
concentration
Avoid use
Moderate CYP3A4 inhibitor + P-gp
inhibitor
Moderate increase in 
concentration
No precaution necessary
Avoid use in patient with severe renal insufficiency
Strong CYP3A4 inducer or
P-gp inducer
Significant reduction in 
concentration
Avoid use
Edoxaban P-gp inhibitor Increase in concentration AF: Do not reduce dose
VTE treatment: Reduce dose
P-gp inducer Significant reduction in 
concentration





Strong CYP3A4 inhibitors+combined P-gp inhibitor Itraconazole, ketoconazole, 
ritonavir
Moderate CYP3A4 inhibitor+combined P-gp inhibitor Clarithromycin, diltiazem
Strong CYP3A4 inducer+combined P-gp inducer Carbamazepine, rifampin, St. 
John’s wort
Strong CYP3A4 inducers Phenytoin









• DOACs have relatively short half-lives. Major bleeding that 
occurs in patients taking DOACs is often able to be managed by 
temporarily discontinuing the anticoagulant and providing 
supportive measures (compression, surgical repair, fluid and/or 
blood replacement).
• Reversing anticoagulation places patients at their baseline 
elevated risk of thromboembolism. Consider restarting 
anticoagulation as soon as medically appropriate.
• Use of reversal agent should only be considered if the bleed is 
life threatening, in a critical organ, or is not controlled with 
supportive measures.
DOAC Reversal agents
• Time (12-24 hours assuming normal renal function)
• Dabigatran (Pradaxa): idarucizumab (Praxabind) is a humanized 
monoclonal antibody fragment that binds to dabigatran. Wholesale 
cost $3500. Approved by FDA October 2015.
• Factor Xa inhibitors (rivaroxaban (Xarleto), apixaban (Eliquis), 
edoxaban (Savaysa), and enoxaparin (Lovenox)): andexanet alfa 
(AndexXa) is a modified recombinant human factor Xa molecule 
that binds and sequesters factor Xa inhibitors, thereby restoring 
thrombin generation and normal hemostatic mechanisms.
3 or 4 factor PCC (prothrombin complex concentrate) (which 
also use for immediate warfarin reversal). 
• The median projected cost of Andexanet was $24750/patient, 
compared to $5670/patient for PCC (P<0.001). The median hospital 
reimbursement for potential Andexanet candidates was 
$26050/hospitalization (71% Medicare, 29% commercial insurance)
US Cost Comparison of DOACs









Copay card* Yes: must not have 
Medicaid or Medicare
Yes: must not have 
Medicaid or Medicare
Yes: must not have 
Medicaid or Medicare
Yes: must not have 
Medicaid or Medicare
Copay $10/mo $5/mo $10/mo $4/mo
Free 30-d
coupon


























• 1) Please make sure the patient is seen in an appointment as there are risks 
of bleeding or thrombosis when you make decisions about perioperative 
anticoagulation.
• 2) Determine and discuss both the risks of bleeding and the risk of 
thrombosis of both the patient’s condition and the planned procedure.
• 3) If needed, discuss risks of the procedure and of bleeding and thrombosis 
with the interventionalist.
• 3) Procedures such as dental procedures, cataracts, and many skin 
procedures can be done on anticoagulation. If the patient is on warfarin, 
make sure the INR is in the therapeutic range.
• 4) Patients with a high risk of thrombosis on warfarin may need bridging 
anticoagulation. DOACs do not need bridging. 
• 5) Post op decide when to restart anticoagulation depending again on risk 
of bleeding and thrombosis. Warn patients of the risk of bleeding or 
clotting.
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